BJDX falls 1.12% as analyst Sell rating holds
Alpha Vantage · AD HOC NEWS · · AI-summarised by FinFlash
Bluejay Diagnostics (BJDX) stock fell 1.12% to USD 0.84 on October 2, 2026, on Nasdaq. Despite an improved cash position of USD 9.6 million in Q2 2026, the company continues to report net losses and its Symphony platform remains investigational, awaiting FDA authorization. An analyst consensus maintains a Sell rating, highlighting the risk associated with its pre-commercial product status.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.